Petition Proposal: Accelerated FDA Approval for Medications for Sanfilippo Syndrome

Introduction:

We, the undersigned, recognize the urgent need for effective treatments for Sanfilippo Syndrome, a rare genetic disorder that severely affects the neurological and physical health of those diagnosed, eventually taking their life in their teenage years if not sooner. Sanfilippo Syndrome, also known as mucopolysaccharidosis type III (MPS III), presents significant challenges to individuals and families, and current treatment options are limited. We believe that expediting the development and approval of medications for Sanfilippo Syndrome is crucial to improving the lives of those affected by this devastating condition. We do not have time to wait.

Statement of Purpose: 

The purpose of this petition is to call upon the United States Food and Drug Administration (FDA) to establish an accelerated approval process specifically for medications intended for the treatment of Sanfilippo Syndrome. Accelerating the review and approval of promising treatments for Sanfilippo Syndrome is essential to providing timely access to potentially life-saving medications for individuals living with this condition.

Key Points:

1. Unmet Medical Need: Sanfilippo Syndrome poses a significant unmet medical need, with currently available treatments providing limited symptomatic relief. Accelerating the development and approval of effective medications is essential to address this urgent medical need.
2. Streamlined Approval Process: We urge the FDA to establish a streamlined approval process that expedites the review of medications for Sanfilippo Syndrome. This process should prioritize the assessment of safety and efficacy based on surrogate endpoints or clinical outcomes reasonably likely to predict long-term therapeutic benefit.
3. Collaboration and Stakeholder Engagement: We call upon the FDA to collaborate with relevant stakeholders, including patient advocacy groups, medical professionals, and researchers, to facilitate the development and evaluation of treatments for Sanfilippo Syndrome. Engaging with the Sanfilippo Syndrome community is essential to ensuring that the needs and perspectives of individuals and families affected by this condition are adequately considered.
4. Post-Approval Monitoring: We emphasize the importance of post-approval monitoring to assess the long-term safety and efficacy of medications approved for Sanfilippo Syndrome. The FDA should require post-marketing studies or trials to further evaluate the benefits and risks of these medications and take appropriate action if safety concerns arise.

Conclusion:

In conclusion, we urge the FDA to take swift and decisive action to accelerate the development and approval of medications for Sanfilippo Syndrome. By establishing an accelerated approval process and collaborating with stakeholders, the FDA can expedite access to potentially life-changing treatments for individuals living with this devastating condition. We call upon the FDA to prioritize the needs of the Sanfilippo Syndrome community and work towards ensuring timely access to effective therapies. Thank you for your attention to this critical issue.

Goal:

With your support and active participation, we are confident that we can surpass our goal of 100,000 signatures within the next 60 days. Together, we can make a powerful statement to the FDA and policymakers, urging them to prioritize the needs of individuals living with Sanfilippo Syndrome and accelerate the approval of life-saving medications. Thank you for joining us in this important endeavor.

Sincerely,

Amber Patrick, aunt to Sanfilippo Syndrome warrior Veda Ulrich

auntfightingsanfilippo@gmail.com

Photo posted of Veda Ulrich, Sanfilippo Warrior.